Placebo + CT-388
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight or Obese
Conditions
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Trial Timeline
Nov 21, 2024 → Nov 30, 2026
NCT ID
NCT06628362About Placebo + CT-388
Placebo + CT-388 is a phase 2 stage product being developed by Roche for Overweight or Obese. The current trial status is active. This product is registered under clinical trial identifier NCT06628362. Target conditions include Overweight or Obese, Type 2 Diabetes Mellitus (T2DM).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06628362 | Phase 2 | Active |
| NCT06525935 | Phase 2 | Completed |
Competing Products
20 competing products in Overweight or Obese
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| LY3457263 + Tirzepatide + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3305677 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3537031 + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection) | Eli Lilly | Phase 2 | 52 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY4064912 + LY4064912 + Placebo + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3437943 + Ethinyl Estradiol + Drospirenone | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Acetaminophen | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3437943 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3502970 + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide and Tirzepatide + Eloralintide | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3541105 + Placebo | Eli Lilly | Phase 1 | 33 |
| Retatrutide + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4167586 + Placebo + LY4167586 | Eli Lilly | Phase 1 | 33 |
| AZD9550 + AZD6234 + Placebo comparator | AstraZeneca | Phase 2 | 52 |